EMA Authorised: Sovaldi (sofosbuvir) — Gilead Sciences Ireland UC

View source ↗

Summary

The European Medicines Agency authorised Sovaldi (sofosbuvir) for chronic hepatitis C, with accelerated assessment noted in the decision. The marketing authoris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sovaldi (Sofosbuvir)

Snippet

Status: Authorised. Therapeutic area: Hepatitis C, Chronic. MAH: Gilead Sciences Ireland UC. Decision date: 12/01/2023. Accelerated assessment